Bioinformatics Tool for Tracking Tumor-Immune Interactions Could Be Useful for Guiding Therapy
A map for discovering immune checkpoints and tumor process interactions is showing potential in identifying new drug targets and personalizing immunotherapy.
Theralink to Become Subsidiary of IMAC via Stock-for-Stock Reverse Merger
Theralink will become a wholly owned subsidiary of IMAC focused on proteomic testing for guiding cancer therapy and drug development.
FDA Sends Byondis Complete Response Letter Delaying Decision on HER2-Positive Breast Cancer Drug
Byondis submitted data on SYD985's activity from the Phase III TULIP trial, but the agency has requested additional information.
EQRx Slashes Headcount, Pipeline in Corporate 'Reset'
The firm is terminating three licensed programs, cutting 170 positions, seeking partnerships for one drug, and prioritizing development of a CDK4/6 inhibitor.
Gilead Sciences Acquires XinThera, Adds PARP1 Inhibitors to Oncology Pipeline
The acquisition will bring several oncology assets into Gilead's pipeline, including a PARP1 inhibitor that may enter clinical trials later this year.